NcXHF

MAWRIN, CHUNG, AND PREUSSER
72. Surace EI, Lusis E, Haipek CA, et al. Functional signifıcance of S6K
overexpression in meningioma progression. Ann Neurol. 2004;56:295-
298.
73. Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress
meningioma growth in mouse models. Clin Cancer Res. 2013;19:1180-
1189.
74. Zhang X, Gejman R, Mahta A, et al. Maternally expressed gene 3, an
imprinted noncoding RNA gene, is associated with meningioma
pathogenesis and progression. Cancer Res. 2010;70:2350-2358.
75. Balik V, Srovnal J, Sulla I, et al. MEG3: a novel long noncoding potentially
tumour-suppressing RNA in meningiomas. J Neurooncol. 2013;
112:1-8.
76. Lusis EA, Watson MA, Chicoine MR, et al. Integrative genomic analysis
identifıes NDRG2 as a candidate tumor suppressor gene frequently
inactivated in clinically aggressive meningioma. Cancer Res.
2005;65:7121-7126.
77. Skiriute D, Tamasauskas S, Asmoniene V, et al. Tumor grade-related
NDRG2 gene expression in primary and recurrent intracranial meningiomas.
J Neurooncol. 2011;102:89-94.
78. Yamaguchi S, Terasaka S, Kobayashi H, et al. Prognostic factors for
survival in patients with high-grade meningioma and recurrence-risk
stratifıcation for application of radiotherapy. PLoS One. 2014;9:
e97108.
79. Ketter R, Henn W, Niedermayer I, et al. Predictive value of
progression-associated chromosomal aberrations for the prognosis of
meningiomas: a retrospective study of 198 cases. J Neurosurg. 2001;95:
601-607.
80. Maillo A, Orfao A, Sayagues JM, et al. New classifıcation scheme for the
prognostic stratifıcation of meningioma on the basis of chromosome
14 abnormalities, patient age, and tumor histopathology. J Clin Oncol.
2003;21:3285-3295.
81. Kim YJ, Ketter R, Henn W, et al. Histopathologic indicators of recurrence
in meningiomas: correlation with clinical and genetic parameters.
Virchows Arch. 2006;449:529-538.
82. Maillo A, Orfao A, Espinosa AB, et al. Early recurrences in histologically
benign/grade I meningiomas are associated with large tumors
and coexistence of monosomy 14 and del(1p36) in the ancestral tumor
cell clone. Neuro Oncol. 2007;9:438-446.
83. Domingues PH, Sousa P, Otero Á, et al. Proposal for a new risk stratifıcation
classifıcation for meningioma based on patient age, WHO tumor
grade, size, localization, and karyotype. Neuro Oncol. 2014;16:
735-747.
84. Weisman AS, Raguet SS, Kelly PA. Characterization of the epidermal
growth factor receptor in human meningioma. Cancer Res. 1987;47:
2172-2176.
85. Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al. Human meningiomas
co-express platelet-derived growth factor (PDGF) and PDGFreceptor
genes and their protein products. Int J Cancer. 1990;46:16-21.
86. Baumgarten P, Brokinkel B, Zinke J, et al. Expression of vascular endothelial
growth factor (VEGF) and its receptors VEGFR1 and
VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol
Histopathol. 2013;28:1157-1166.
87. Lichtor T, Kurpakus MA, Gurney ME. Expression of insulin-like
growth factors and their receptors in human meningiomas. J Neurooncol.
1993;17:183-190.
88. Johnson MD, Woodard A, Kim P, et al. Evidence for mitogenassociated
protein kinase activation and transduction of mitogenic signals
by platelet-derived growth factor in human meningioma cells.
J Neurosurg. 2001;94:293-300.
89. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogenactivated
protein kinase and Akt signaling is associated with aggressive
phenotype of human meningiomas. Clin Cancer Res. 2005;11:4074-
4082.
90. Johnson MD, Okedli E, Woodard A, et al. Evidence for phosphatidylinositol
3-kinase-Akt-p7S6K pathway activation and transduction of
mitogenic signals by platelet-derived growth factor in meningioma
cells. J Neurosurg. 2002;97:668-675.
91. Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor
gene NF2, encoding merlin, constitutively activates integrindependent
mTORC1 signaling. Mol Cell Biol. 2009;29:4235-4249.
92. James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative
regulator of mTOR complex 1, and activation of mTORC1 is associated
with meningioma and schwannoma growth. Mol Cell Biol. 2009;
29:4250-4261.
93. Castelli MG, Chiabrando C, Fanelli R, et al. Prostaglandin and thromboxane
synthesis by human intracranial tumors. Cancer Res. 1989;49:
1505-1508.
94. Kang HC, Kim IH, Park CI, et al. Immunohistochemical analysis of
cyclooxygenase-2 and brain fatty acid binding protein expression in
grades I-II meningiomas: correlation with tumor grade and clinical
outcome after radiotherapy. Neuropathology. 2014;34:446-454.
95. Johnson MD, Horiba M, Winnier AR, et al. The epidermal growth factor
receptor is associated with phospholipase C-gamma 1 in meningiomas.
Hum Pathol. 1994;25:146-153.
96. Johnson MD, Shaw AK, O’Connell MJ, et al. Analysis of transforming
growth factor beta receptor expression and signaling in higher grade
meningiomas. J Neurooncol. 2011;103:277-285.
97. Nagashima G, Asai J, Suzuki R, et al. Different distribution of c-myc
and MIB-1 positive cells in malignant meningiomas with reference to
TGFs, PDGF, and PgR expression. Brain Tumor Pathol. 2001;18:1-5.
98. Johnson MD, O’Connell MJ, Vito F, et al. Bone morphogenetic protein
4 and its receptors are expressed in the leptomeninges and meningiomas
and signal via the Smad pathway. J Neuropathol Exp Neurol. 2009;
68:1177-1183.
99. Bindal R, Goodman JM, Kawasaki A, et al. The natural history of untreated
skull base meningiomas. Surg Neurol. 2003;59:87-92 (discussion,
92).
100. Simpson D. The recurrence of intracranial meningiomas after surgical
treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39.
101. Sughrue ME, Kane AJ, Shangari G, et al. The relevance of Simpson
grade I and II resection in modern neurosurgical treatment of World
Health Organization grade I meningiomas. J Neurosurg. 2010;113:
1029-1035.
102. Larson JJ, van Loveren HR, Balko MG, et al. Evidence of meningioma
infıltration into cranial nerves: clinical implications for cavernous sinus
meningiomas. J Neurosurg. 1995;83:596-599.
103. O’Sullivan MG, van Loveren HR, Tew JM Jr. The surgical resectability
of meningiomas of the cavernous sinus. Neurosurgery. 1997;40:238-
244 (discussion, 245-247).
104. Suzuki M, Mizoi K, Yoshimoto T. Should meningiomas involving the
cavernous sinus be totally resected? Surg Neurol. 1995;44:3-10 (discussion
10-13).
105. Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal versus
open transcranial resection of anterior midline skull base meningiomas.
World neurosurg. 2012;77:713-724.
106. Rachinger W, Grau S, Tonn JC. Different microsurgical approaches to
meningiomas of the anterior cranial base. Acta Neurochir (Wein).
2010;152:931-939.
107. Mathiesen T, Lindquist C, Kihlström L, et al. Recurrence of cranial
base meningiomas. Neurosurgery. 1996;39:2-7 (discussion, 8-9).
108. Dziuk TW, Woo S, Butler EB, et al. Malignant meningioma: an indication
for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol.
1998;37:177-188.
e114
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook